MENU
APR 20, 2021 3:00 PM PDT

Panel Presentation: Accelerating precision oncology with matched FFPE and plasma biospecimens characterized using Discovery's SpecimenSeq™ NGS Service and QIAGEN's QIAseq Multimodal Panels

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Product Manager, Biospecimens and Cell Services, Discovery Life Sciences
    Biography

      Nathan studies biology and graduated from The University of Alabama in Huntsville in 2014. He quickly entered the workforce handling the logistics of biological samples at Lifesouth Community Blood Centers (2014) and Conversant Bio (2017). Nathan then began serving as a feasibility associate and was responsible for evaluating all prospective customer projects. He currently serves as the Product Manager for Biospecimens and CellServices at Discovery Life Sciences. 

    • Sr. Vice President, Genomics, Discovery Life Sciences
      Biography

        Don received his PhD in pharmacology and neuroscience focusing on the molecular and genetic mechanisms of learning and memory at the University of Nebraska Medical Center in 2002. He received his MBA from the University of Nebraska Omaha in 2001. On the heels of the completion of the human genome project in 2003, following a post-doctoral fellowship in Cambridge, MA, he pursued a career in the commercialization of genomic technologies and next generation sequencing services. Don's work history includes Commercial and Technical Application Support leadership roles at several genomic technology and services companies including Invitrogen (now Thermo Fisher Scientific), Sequenom (now Agena Bioscience), Complete Genomics (IPO in 2010), the Broad Institute, and OneOme (a start-up pharmacogenomics spinout of the Mayo Clinic). He currently serves as the Senior Vice President, Genomics within the HudsonAlpha Discovery Genomics division of Discovery Life Sciences.


      Abstract

      Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched SpecimenSeq product line makes this challenge easier for targeted oncology and liquid biopsy developers by delivering access to ethically collected biospecimen sets that are annotated with genomic and clinical characteristics. Join this webinar to learn how Discovery’s SpecimenSeq NGS Service and QIAGEN Multimodal Panels can help you advance precision oncology programs by:

      • Efficiently verifying the presence of biomarker targets in study populations of interest

      • Building study cohorts with confirmed driver mutations and other clinically relevant genomic variants across FFPE and matched plasma samples

      • Accelerating timelines and reducing the cost of studies designed to:

      o Identify responders versus non-responders

      o Evaluate efficacy

      o Discover and validate biomarker signatures for new liquid biopsy and other diagnostic tests as well as targeted therapies

      Learning Objectives:

      1. Efficient verification of the presence of biomarker targets in study populations of interest 

      2. Build study cohorts with confirmed driver mutations and other clinically relevant genomic variants across FFPE and matched plasma samples 

      3. Accelerate timelines and reduce cost of studies 


      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      FEB 24, 2021 10:00 AM PST
      C.E. CREDITS
      FEB 24, 2021 10:00 AM PST
      DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      MAR 16, 2021 10:00 AM PDT
      C.E. CREDITS
      MAR 16, 2021 10:00 AM PDT
      Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
      Loading Comments...
      Show Resources
      Attendees
      • See more